Definitive Contract HHSO100201000026C
Award Date
12/18/09
Potential Completion Date
9/30/18
Potential Value
$138M
Awardee
Elusys Therapeutics Inc.
Ultimate Awardee
Nighthawk Biosciences, Inc.
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Pine Brook, Montville, NJ 07058, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm-fixed price delivery order contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Elusys Therapeutics Inc., a self-certified small disadvantaged business. The contract, valued at $24,501,100.00, is for "ANTHIM LETTER CONTRACT" and "FOR OTHER FUNCTIONS" services in the area of biomedical research and development. The contract has no set-aside designation and the period of...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response awarded a $79,947,200.00 Firm Fixed Price contract to Elusys Therapeutics Inc. for the manufacture and vendor managed inventory of Anthim (obiltoxaximab) 600mg/6ml for Injection, an FDA-approved anthrax antitoxin. The contract has a period of performance from August 6, 2021 through September 14, 2024, and includes options for additional manufacturing and delivery of finished drug...
This is a firm fixed price delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency under the Department of Health and Human Services (HHS), to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The $196,434,000 award is for the provision of anthrax antitoxins to treat inhalational anthrax, under the agency's medical countermeasures development and procurement program. The...
This federal contract award, valued at $330,136,246.14, was granted by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to 4J Therapeutics Inc., a self-certified small disadvantaged business. The contract's objective is to demonstrate the versatility and efficacy of 4J Therapeutics' programmable antiviral technology platform by assembling a preclinical package for LNA14, performing a Phase 1a...
This is a $99,941,719.80 definitive, firm fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense, on March 16, 2017. The contract has an ultimate completion date of March 15, 2019 and is not set aside. Emergent Biodefense is a for-profit manufacturer of medical countermeasures and biopharmaceuticals, specializing in vaccines and therapeutics for public health...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
<p>This is a $98,144,230.00 definitive, cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to The Medicines Company on September 15, 2016. The contract is to advance the development of a portfolio of anti-infective programs. There is no set-aside designation indicated. The contract has an ultimate completion date of September 30, 2030.</p>
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The $29,026,970.00 cost-plus-fixed-fee contract was awarded on September 9, 2019 to perform work under HHS-NIH-NIAID-BAA2018. The contract has an ultimate completion date of August 17, 2024 and does not have a set-aside designation....
This federal contract award, valued at $228,598,975.00, was issued by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Janssen Research & Development, LLC. The award is not associated with a set-aside designation. The contract is for the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats, in support of ASPR's Public Health...